The Conversation (0)
SDIX (NASDAQ:SDIX), a provider of biotechnology products and services, announced that it has inked a deal with OriGene Technologies to sell the former’s life science business for $16 million. OriGene has agreed to offer employment to majority of SDIX’s employees.
SDIX (NASDAQ:SDIX), a provider of biotechnology products and services, announced that it has inked a deal with OriGene Technologies to sell the former’s life science business for $16 million. OriGene has agreed to offer employment to majority of SDIX’s employees.
As quoted in the press release:
Francis DiNuzzo, SDIX’s President and CEO, commented, “The sale of our Life Science business to OriGene is a natural progression for SDIX. The combination of our core Life Science business and our Advanced GAT technologies with OriGene’s technologies and global operations will result in a broader portfolio of products and services for our customer base and a reach into markets that SDIX would be challenged to achieve as a standalone business.
Click here to read the full SDIX (NASDAQ:SDIX) press release.